Other medications are approved for rare obesity subtypes, as opposed to general obesity, such as Metreleptin for congenital or acquired generalized lipodystrophy and Setmelanotide for individuals with genetic variants of obesity (e.g., proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, leptin receptor). This evidence concerns the gene POMC and obesity disorder.